Ophthalmology and therapy · 2026
Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teo Kelvin Yi Chong, Yoon Young Hee, Honda Shigeru, Park Kyu Hyung, Takahashi Hidenori, Ideta Ryuichi, Sekiryu Tetsuju, Hirata Akira, Obana Akira, Mori Ryusaburo, Chen Shih-Jen, Chee Caroline, Wong James G, Lai Timothy Y Y, Wong Ian, Fung Nick, Lee Won Ki, Terasaki Hiroko, Chen Shih-Chou, Miyatani Takafumi, Iida Tomohiro, Obata Ryo, Machewitz Tobias, Leal Sergio, Cheung Chui Ming Gemmy
Аннотация
INTRODUCTION: The PLANET study demonstrated that intravitreal aflibercept 2 mg injection (IAI) monotherapy was non-inferior to IAI with rescue photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) at 2 years. This follow-up study assessed the long-term outcomes 6 years after initiation of IAI therapy in the PLANET cohort.
METHODS: This was a non-interventional cohort study of 72 patients with PCV from six international sites who originally completed the PLANET study. Outcomes were assessed during a recall visit at ~6 years from PLANET enrollment. Data collected included best-corrected visual acuity (BCVA), optical coherence tomography, treatment exposure, and adverse events. Patients were treated according to standard of care after exiting from the PLANET study.
RESULTS: Of 72 participants, 32 were randomized to IAI monotherapy and 40 to IAI with rescue PDT. Of those randomized to IAI with rescue PDT, 11 (15.2%) received rescue PDT during the entire study period over 6 years. Mean ± standard deviation (SD) BCVA improved by 14.6 ± 10.3 letters at 2 years but declined to baseline by 6 years (-0.3 ± 21.8 letters). At year 6, 45.8% of eyes had BCVA ≥ 69 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, while 23.6% had < 36 ETDRS letters. Polypoidal lesions were present in 69.4% at year 2 versus 29.2% at year 6. Patients received a mean ± SD of 10.2 ± 2.9 anti-vascular endothelial growth factor (anti-VEGF) injections between years 2-6. Outcomes were better in reimbursed versus non-reimbursed regions. Multivariable analysis showed that younger age and better mean BCVA at year 2 predicted more favorable long-term vision. PDT received at any time was not associated with overall mean BCVA at year 6, although it was associated with a lower risk of ≥ 15-letter loss.
CONCLUSION: At 6 years, initial visual gains from aflibercept therapy were not maintained; however, nearly half of the eyes had BCVA ≥ 69 letters, and a large proportion achieved polypoidal lesion regression.
TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT002120950.
METHODS: This was a non-interventional cohort study of 72 patients with PCV from six international sites who originally completed the PLANET study. Outcomes were assessed during a recall visit at ~6 years from PLANET enrollment. Data collected included best-corrected visual acuity (BCVA), optical coherence tomography, treatment exposure, and adverse events. Patients were treated according to standard of care after exiting from the PLANET study.
RESULTS: Of 72 participants, 32 were randomized to IAI monotherapy and 40 to IAI with rescue PDT. Of those randomized to IAI with rescue PDT, 11 (15.2%) received rescue PDT during the entire study period over 6 years. Mean ± standard deviation (SD) BCVA improved by 14.6 ± 10.3 letters at 2 years but declined to baseline by 6 years (-0.3 ± 21.8 letters). At year 6, 45.8% of eyes had BCVA ≥ 69 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, while 23.6% had < 36 ETDRS letters. Polypoidal lesions were present in 69.4% at year 2 versus 29.2% at year 6. Patients received a mean ± SD of 10.2 ± 2.9 anti-vascular endothelial growth factor (anti-VEGF) injections between years 2-6. Outcomes were better in reimbursed versus non-reimbursed regions. Multivariable analysis showed that younger age and better mean BCVA at year 2 predicted more favorable long-term vision. PDT received at any time was not associated with overall mean BCVA at year 6, although it was associated with a lower risk of ≥ 15-letter loss.
CONCLUSION: At 6 years, initial visual gains from aflibercept therapy were not maintained; however, nearly half of the eyes had BCVA ≥ 69 letters, and a large proportion achieved polypoidal lesion regression.
TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT002120950.